The TRANSCEND trial evaluated the efficacy and safety of setmelanotide for the treatment of acquired hypothalamic obesity.

The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics Application (sBLA) for fremanezumab-vfrm to include the ...

Erzofri is an atypical antipsychotic that is administered once a month as an intramuscular injection by a health care professional.

Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide.

Findings seen in patients with posterior circulation stroke and with no planned thrombectomy who received alteplase 4.5 to 24 hours after stroke onset.

GLP-1 receptor agonist prescriptions increased significantly during study period across all categories of BMI, in dose-response manner.

The delay dovetails with moves by Republican lawmakers in at least 7 states to ban or limit mRNA vaccines. Some, according to KFF Health News, are also pressing regulators to revoke federal approval ...

The Food and Drug Administration (FDA) has cleared the Visby Medical Women’s Sexual Health Test for use at home to test for ...

BIIB080 is an antisense oligonucleotide therapy designed to target microtubule-associated protein tau mRNA and reduce the production of tau.

The Food and Drug Administration (FDA) has approved Uplizna ® (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease (IgG4-RD) in adult patients.

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.